RudaCure attended the 19th Annual Pain Therapeutics Summit held in San Diego from October 13-14, 2025, gaining insights into the latest changes and research trends in the thérapeutiques de la douleur market. At the event, l'entreprise engaged in active networking with major entreprises pharmaceutiques notamment Eli Lilly, Merck, Roche, and J&J, sharing clinical strategies and thérapeutiques de la douleur market trends.
The summit featured presentations and discussions on the latest research into novel traitement de la douleur targets by numerous groups, with a focus on essai clinique design for pain développement de médicaments, emerging pain targets, and advanced thérapeutiques. RudaCure established ongoing networks with companies showing strong interest in its innovant candidat-médicament RCI002, creating opportunities to discuss future concession de licence strategies and technology development directions.
L'entreprise is preparing to unveil RCI002 l'année prochaine and will strengthen collaboration with global entreprises pharmaceutiques to actively pursue expansion mondiale du marché.
